Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Saad, Fred, Clarke, Noel W, Oya, Mototsugu, Shore, Neal, Procopio, Giuseppe, Guedes, João Daniel, Arslan, Cagatay, Mehra, Niven, Parnis, Francis, Brown, Emma, Schlürmann, Friederike, Joung, Jae Young, Sugimoto, Mikio, Sartor, Oliver, Liu, Yu-Zhen, Poehlein, Christian, Barker, Laura, del Rosario, Paula Michelle, Armstrong, Andrew J
Published in The lancet oncology (01.10.2023)
Published in The lancet oncology (01.10.2023)
Get full text
Journal Article
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy en‑dpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOT-EN10 Trial
Baurain, Jean-Francois, Chon, Hye Sook, Pepin, Jessica Thomes, Sundborg, Michael, Gold, Michael, Kim, Byoung-Gie, Blank, Stephanie, Liu, Ji-Hong, McCollum, Michael, Mori, Masahiko, Jonuskiene, Goda, Moore, Kathleen, Novak, Zoltan, Guette, Pedro Luis Ramos, de Pádua, Charles Andreé Joseph, Martin, Marta Gil, Kowgier, Matthew, del Rosario, Paula Michelle, Westin, Shannon, Van Nieuwenhuysen, Els
Published in Gynecologic oncology (01.11.2024)
Published in Gynecologic oncology (01.11.2024)
Get full text
Journal Article
Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial
Shore, Neal D., Clarke, Noel, Armstrong, Andrew J., Oya, Mototsugu, Procopio, Giuseppe, Guedes, João Daniel Cardoso, Arslan, Cagatay, Mehra, Niven, Brown, Emma, Schlürmann, Friederike, Joung, Jae Young, Sugimoto, Mikio, Vianna, Karina, Hosius, Christian, Barnicle, Alan, Liu, Yu-Zhen, Harrington, Elizabeth, McGuinness, David, del Rosario, Paula Michelle, Saad, Fred
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
MP11-16 PROSTATE-SPECIFIC ANTIGEN ANALYSES IN PROPEL: ABIRATERONE AND OLAPARIB VERSUS ABIRATERONE AND PLACEBO AS FIRST-LINE THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Saad, Fred, Armstrong, Andrew J., Thiery-Vuillemin, Antoine, Oya, Mototsugu, Shore, Neal, Procopio, Giuseppe, Guedes, Joao Daniel, Arslan, Cagatay, Mehra, Niven, Parnis, Francis, Park, Kurralta, Australia, Brown, Emma, Schlürmann, Friederike, Joung, Jae Young, Sugimoto, Mikio, Sartor, A. Oliver, Poehlein, Christian, Harrington, Elizabeth A., Barker, Laura, Michelle del Rosario, Paula, Clarke, Noel
Published in The Journal of urology (01.04.2023)
Published in The Journal of urology (01.04.2023)
Get full text
Journal Article
Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)
Clarke, Noel W., Armstrong, Andrew J., Thiery-Vuillemin, Antoine, Oya, Mototsugu, Shore, Neal D., Procopio, Giuseppe, Guedes, João Daniel Cardoso, Arslan, Cagatay, Mehra, Niven, Parnis, Francis, Brown, Emma, Schlürmann, Friederike, Joung, Jae Young, Sugimoto, Mikio, Sartor, A. Oliver, Liu, Yu-Zhen, Poehlein, Christian Heinrich, Barker, Laura, del Rosario, Paula Michelle, Saad, Fred
Published in Journal of clinical oncology (20.02.2023)
Published in Journal of clinical oncology (20.02.2023)
Get full text
Journal Article